Rathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D., Lakhani, N., Hawley, J. E., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K. D., Emamekhoo, H., Reichert, Z. R., Nguyen, M. H., Wells, A. L., Kandimalla, R., Liu, C., Suryawanshi, S., Han, J., Wu, J., … Armstrong, A. J. (2024). Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2024.09.005

Mckean, M., Chmielowski, B., Butler, M. O., Carvajal, R., Rodon, J., Carlino, M., Kim, K. B., Wise-draper, T., Khan, S., Salama, A. K. S., Moser, J., Reeves, J., Wilner, K. D., Maurer, M., Abed, M., Mitchell, B., Beaupre, D., & Orloff, M. (2023). 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). Annals of Oncology, 34, S651. https://doi.org/10.1016/j.annonc.2023.09.2215

Patel, S., Mckean, M., Piperno-Neumann, S., Shoushtari, A. N., Hernandez-Aya, L., Orloff, M., Khan, S., Montazeri, K., Kapiteijn, E., Buchbinder, E., Agresta, S., Reilly, S., Patriquin, C. M., Hickman, D., Corrigan, D., Granlund, L., Hentemann, M., Piel, J., Martin, P., & Mehmi, I. (2023). 1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma. Annals of Oncology, 34, S677–S678. https://doi.org/10.1016/j.annonc.2023.09.2262

Orloff, M., Watkins, C., Carvajal, R. D., Shoushtari, A. N., Sacco, J. J., Schlaak, M., Gama, J., & Butler, M. O. (2023). 1129P Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up. Annals of Oncology, 34, S678. https://doi.org/10.1016/j.annonc.2023.09.2263

LaRose, M., Zhou, M., Lu, S., Wei, H., Bates, S. E., Schwartz, L., & Fojo, A. T. (2023). 1328P Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib. Annals of Oncology, 34, S766–S767. https://doi.org/10.1016/j.annonc.2023.09.2361

Wilky, B., Trent, J. C., Gordon, M., El-Khoueiry, A. B., Bullock, A., Henick, B. S., Schwartz, G. K., Agulnik, M., Mahadevan, D., Patel, J., Grossman, J., Rosenthal, K., O’Day, S. J., & Tsimberidou, A. M. (2023). 1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma. Annals of Oncology, 34, S1032–S1033. https://doi.org/10.1016/j.annonc.2023.09.1148

Van Tine, B. A., Ingham, M. A., Attia, S., Meyer, C. F., Baird, J. D., D’Silva, D., O’Keefe, K., Kong, R., Maliakal, P., Gao, L., & Schwartz, G. K. (2023). 1934P Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma. Annals of Oncology, 34, S1039. https://doi.org/10.1016/j.annonc.2023.09.1163

Xiang-Xu, W., Jing-Yi, R., Xiao-Wen, W., & Hong-Mei, Z. (2023). 1935P Exploration of tertiary lymphatic structure in soft tissue sarcoma for the prognostic and immunotherapy response. Annals of Oncology, 34, S1039–S1040. https://doi.org/10.1016/j.annonc.2023.09.1164

Basu, A., Umashankar, S., Musthafa, M., Jones, T., Blevins, K., Brown, T., Heditsian, D., Parker, B., Brain, S., Simmons, C., Hieken, T. J., Ruddy, K., Mainor, C., Tevis, S., Blaes, A., Rugo, H. S., Dunn, I., Melisko, M., Esserman, L., & Hershman, D. L. (2023). 374P Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial. Annals of Oncology, 34, S332–S333. https://doi.org/10.1016/j.annonc.2023.09.552

Shi, W., Glas, M., Mrugala, M. M., Iwamoto, F. M., Lukas, R. V., Palmer, J., & Suh, J. (2023). 529P Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022. Annals of Oncology, 34, S402. https://doi.org/10.1016/j.annonc.2023.09.1723

O’Cearbhaill, R. E., Moore, K. N., Yeku, O., Liu, J. F., Bouberhan, S., Hamilton, E. P., Hou, J. Y., Van Nieuwenhuysen, E., Papadimitriou, K., Yoo, S.-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Madia, P., Zhu, M., Uldrick, T. S., Miller, E. A., & O’Malley, D. (2023). 754P Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study. Annals of Oncology, 34, S516–S517. https://doi.org/10.1016/j.annonc.2023.09.1933

Le, X., Patel, J., Shum, E., Sanborn, R. E., Baik, C. S., Shu, C. A., Kim, C., Fidler, M. D., Hall, R., Hanna, N., Mohindra, N., Sabari, J. K., Heeke, S., Hernandez, M., Gray, J. E., Heymach, J. V., & Saltos, A. (2023). LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis). Annals of Oncology, 34, S1313–S1314. https://doi.org/10.1016/j.annonc.2023.10.072

Bullock, A., Fakih, M., Gordon, M., Tsimberidou, A., El-Khoueiry, A., Wilky, B., Pimentel, A., Margolin, K., Mahadevan, D., Balmanoukian, A., Sanborn, R., Schwartz, G., Abou-Alfa, G., Bockorny, B., Moser, J., Sharma, S., Grossman, J., Rosenthal, K., O’Day, S., … Schlechter, B. (2023). LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). Annals of Oncology, 34, S178–S179. https://doi.org/10.1016/j.annonc.2023.04.014

Laderian, B., Wei, W., Farha, N., Mundi, P., Rao, P., Balagamwala, E., Steele, S., Vijayvergia, N., Sadaps, M., Chandrasekharan, C., Mohamed, A., & Pacak, K. (2023). P-136 Increased healthcare costs due to diagnostic imaging services following false elevation of plasma chromogranin A and 24-hour urinary 5-hydroxyindoleacetic acid: A quality improvement project. Annals of Oncology, 34, S63. https://doi.org/10.1016/j.annonc.2023.04.192

Farha, N., Wei, W., Mundi, P., Krishnamurthi, S., Steele, S., Kamath, S., Gorgun, E., Liska, D., Estfan, B., Khorana, A., & Laderian, B. (2023). P-273 Genomic signatures associated with aggressive histology and decreased overall survival in neuroendocrine malignancies. Annals of Oncology, 34, S112. https://doi.org/10.1016/j.annonc.2023.04.329

Araujo, D., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., de Bono, J., Drilon, A., Garralda, E., Ivy, P., Kholmanskikh, O., Melero, I., Pentheroudakis, G., Petrie, J., Plummer, R., Ponce, S., Postel-Vinay, S., Siu, L., Spreafico, A., … Seymour, L. (2023). Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Annals of Oncology, 34(1), 48–60. https://doi.org/10.1016/j.annonc.2022.09.158

Lim, E., Reeves, J., Gandhi, S., Spigel, D. R., Arrowsmith, E., George, D. J., Karlix, J., Pouliot, G., Hattersley, M., Gangl, E., James, G., Thompson, J., Russell, D., Patel, B., Kumar, R., & Falchook, G. S. (2022). 1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology, 33, S1182–S1183. https://doi.org/10.1016/j.annonc.2022.07.1882

Ingham, M., Blay, J.-Y., Baird, J., D’Silva, D., O’Keefe, K., Kong, R., Spiegel, R., Wahba, M., & Weetall, M. (2022). 1528TiP A phase II/III study evaluating the efficacy and safety of unesbulin in advanced leiomyosarcoma (SUNRISELMS). Annals of Oncology, 33, S1243–S1244. https://doi.org/10.1016/j.annonc.2022.07.1917

Yap, T. A., Moore, K. N., Patel, M., Henick, B. S., Do, D., Iheanacho, A., Zhang, H., Roche, M., Newberry, K., Hsieh, A., & Juric, D. (2022). 491TiP A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors. Annals of Oncology, 33, S765. https://doi.org/10.1016/j.annonc.2022.07.619

Johnson, M. L., Rodon, J., Aljumaily, R., Villalona-Calero, M., Borazanci, E., Pishvaian, M., Turk, A., Carvajal, R. D., Mantia, C., Giaccone, G., Mounir, Z., Patel, A., Maurer, M., Neilan, C., Rajendran, D., Ganesan, U., Hinkle, J., & Tolcher, A. W. (2022). 492TiP A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion. Annals of Oncology, 33, S766–S767. https://doi.org/10.1016/j.annonc.2022.07.620

Van Nieuwenhuysen, E., O’Malley, D., O’Cearbhaill, R. E., Moore, K. N., Hamilton, E. P., Yeku, O., Bouberhan, S., Hou, J. Y., Yoo, S.-Y., Brouwer-Visser, J., Cheung, H. K., Peterman, M., Goncalves, P., Schmidt, T., Zhu, M., Lowy, I., Rowlands, T., Uldrick, T. S., Miller, E. A., & Liu, J. F. (2022). 523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis. Annals of Oncology, 33, S784. https://doi.org/10.1016/j.annonc.2022.07.651

Hamid, O., Sato, T., Davar, D., Callahan, M. K., Thistlethwaite, F., Aljumaily, R., Johnson, M. L., Arkenau, H.-T., Ileana Dumbrava, E. E., Izar, B., Chen, H. A., Marshall, S., Yuan, Y., Deo, M., Stanhope, S., Collins, L., Mundy, R., Abdullah, S. E., & Lopez, J. S. (2022). 728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. Annals of Oncology, 33, S875. https://doi.org/10.1016/j.annonc.2022.07.854

Kyi, C. K., Spira, A., Carbone, D. P., Johnson, M. L., Henick, B. S., Johnson, B., Borghaei, H., Mahipal, A., Hecht, J. R., Catenacci, D., Liao, C.-Y., Shergill, A., Memmott, R., Presley, C., Jaroslavsky, J., Schenk, D., Jooss, K., Ferguson, A. R., & Goldman, J. W. (2022). 736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS). Annals of Oncology, 33, S880. https://doi.org/10.1016/j.annonc.2022.07.862

Dimitriou, F., Hassel, J. C., Orloff, M., Hughes, I., Kapiteijn, E., Mehmi, I., Montazeri, K., Johnson, D. B., Grover, P., Gerard, C. L., Simeone, E., Gaudy Marqueste, C., Cheng, P., Long, G. V., Carvajal, R. D., & Dummer, R. (2022). 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology, 33, S929. https://doi.org/10.1016/j.annonc.2022.07.958

Sato, T., Ikeguchi, A. P., Nathan, P., Carvajal, R. D., Shoushtari, A. N., Gajewski, T. F., Hassel, J. C., Rioth, M., Leyvraz, S., Daniels, G. A., Hernandez-Aya, L., Johnson, D. B., Kim, K., Piulats Rodriguez, J. M., Cowey, C. L., Lockwood, S., Collins, L., Karakuzu, O., Sacco, J. J., & Butler, M. O. (2022). 843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma. Annals of Oncology, 33, S934–S935. https://doi.org/10.1016/j.annonc.2022.07.969

Pass, H., Kim, A. W., Felip, E., Shu, C. A., Ferris, A., Frueh, M., Gitlitz, B. J., Troutman, S., Petrek, H., Liu, X., Hsu, J., Patil, N., & Meng, R. D. (2022). 970TiP SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC. Annals of Oncology, 33, S990–S991. https://doi.org/10.1016/j.annonc.2022.07.1096

Dimitriou, F., Namikawa, K., Reijers, I. L. M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K. C., … Long, G. V. (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33(9), 968–980. https://doi.org/10.1016/j.annonc.2022.06.004

Park, K., Sabari, J., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2022). MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study. Annals of Oncology, 33, S482. https://doi.org/10.1016/j.annonc.2022.05.104

Hassan, H., Vanessa, W., Zemla, T., Yin, J., Prasai, K., Abdellatief, A., Katta, R., Tran, N., & Mahipal, A. (2022). P-181 Outcomes of neoadjuvant and/or adjuvant treatment vs surgical resection alone for patients with cholangiocarcinoma: An inverse probability of treatment weighting with predictive nomogram. Annals of Oncology, 33, S314. https://doi.org/10.1016/j.annonc.2022.04.271

Yap, C., Solovyeva, O., Yin, Z., Martin, J., Manickavasagar, T., Weir, C., Lee, S., Dimairo, M., Liu, R., Kightley, A., & de Bono, J. S. (2022). 53P Assessing the reporting quality of early phase dose-finding trials. Annals of Oncology, 33, S24. https://doi.org/10.1016/j.annonc.2022.01.018

Schmidt, A. L., Labaki, C., Hsu, C.-Y., Bakouny, Z., Balanchivadze, N., Berg, S. A., Blau, S., Daher, A., El Zarif, T., Friese, C. R., Griffiths, E. A., Hawley, J. E., Hayes-Lattin, B., Karivedu, V., Latif, T., Mavromatis, B. H., McKay, R. R., Nagaraj, G., Nguyen, R. H., … Warner, J. L. (2022). COVID-19 vaccination and breakthrough infections in patients with cancer. Annals of Oncology, 33(3), 340–346. https://doi.org/10.1016/j.annonc.2021.12.006

Sharma, M. R., Carvajal, R. D., Hanna, G. J., Kang, Y. K., Lee, J., Lee, K. W., Li, B. T., Moore, K. N., Pegram, M., Rasco, D., Spira, A., Wang, D., Weinberg, B. A., Alonso, M., Fang, L., Husain, A., Kowanetz, M., Perez, E. A., & Dumbrava, E. I. (2021). 164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. Annals of Oncology, 32, S1453–S1454. https://doi.org/10.1016/j.annonc.2021.10.183

Sommerhalder, D., Lim, E. A., Pande, A., & Keller, P. (2021). 1035TiP A phase I/Ib study of MPT-0118 as monotherapy and in combination with pembrolizumab in subjects with advanced or metastatic solid tumors. Annals of Oncology, 32, S866. https://doi.org/10.1016/j.annonc.2021.08.1419

Leighl, N. B., Shu, C. A., Minchom, A., Felip, E., Cousin, S., Cho, B. C., Park, K., Han, J.-Y., Boyer, M., Lee, C. K., Garcia, V. M., Tomasini, P., Viteri, S., Xie, J., Mertz, J., Artis, E., Schnepp, R. W., Knoblauch, R. E., Thayu, M., & Perez, J. M. T. (2021). 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study. Annals of Oncology, 32, S951–S952. https://doi.org/10.1016/j.annonc.2021.08.1797

Shu, C. A., Goto, K., Ohe, Y., Besse, B., Park, K., Wang, Y., Griesinger, F., Yang, J. C.-H., Felip, E., Sanborn, R. E., Caro, R. B., Bauml, J. M., Chen, J., Fennema, E., Mahoney, J., Trani, L., Knoblauch, R. E., Thayu, M., & Cho, B. C. (2021). 1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2. Annals of Oncology, 32, S952–S953. https://doi.org/10.1016/j.annonc.2021.08.1798

Park, K., Sabari, J. K., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2021). 1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab. Annals of Oncology, 32, S981–S982. https://doi.org/10.1016/j.annonc.2021.08.1852

Peters, S., Rizvi, N. A., Kuziora, M., Lai, Z., Shrestha, Y., Dey, A., Barrett, J. C., Scheuring, U., Poole, L., Abbosh, C., Raja, R., & Hellmann, M. D. (2021). 1264P Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial. Annals of Oncology, 32, S989–S990. https://doi.org/10.1016/j.annonc.2021.08.1866

Loibl, S., Loirat, D., Tolaney, S. M., Punie, K., Oliveira, M., Rugo, H. S., Bardia, A., Hurvitz, S. A., Brufsky, A., Kalinsky, K., Cortés, J., O’Shaughnessy, J., Dieras, V. C., Carey, L. A., Gianni, L., Gharaibeh, M., Moore, L., Shi, L., & Piccart, M. (2021). 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). Annals of Oncology, 32, S472–S473. https://doi.org/10.1016/j.annonc.2021.08.540

Mckean, M. A., Lakhani, N. J., Arkenau, H.-T., Symeonides, S., Evans, T. R. J., Lim, E. A., Fontana, E., Bupathi, M., Mclaren, A., Chandana, S. R., Ding, T.-E., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., Bexon, A., & Falchook, G. S. (2021). 525P Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors. Annals of Oncology, 32, S592. https://doi.org/10.1016/j.annonc.2021.08.1047

Abramson, V., Linden, H. M., Crew, K., Mortimer, J., Alidzanovic, J., Nangia, J., Layman, R., Vranjes, Z. J., Andric, Z., Milovic-Kovacevic, M., Trifunovic, J., Karchmit, Y., Suarez, J., Suster, M., Ptaszynski, M., & Chalasani, P. (2021). 565TiP A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer. Annals of Oncology, 32, S619. https://doi.org/10.1016/j.annonc.2021.08.1087

Catenacci, D. V., Liao, C.-Y., Maron, S., Solomon, B. J., Mahipal, A., Johnson, M. L., Carbone, D., Henick, B. S., Johnson, B., Roychowdhury, S., Mody, K., Ahn, D. H., Bournazou, E., Schenk, D., Kounlavouth, S., Kraemer, L., Talbot, G., Rousseau, R., Ferguson, A. R., & Spira, A. (2021). 960MO Clinical outcomes and immune responses in a phase I/II study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC. Annals of Oncology, 32, S830–S831. https://doi.org/10.1016/j.annonc.2021.08.1345

Bardia, A., Tolaney, S. M., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A., Aftimos, P., Dalenc, F., Sardesai, S., Hamilton, E., Sharma, P., Recalde, S., Gil, E. C., Traina, T., O’Shaughnessy, J., Cortes, J., Tsai, M., Vahdat, L., … Hurvitz, S. A. (2021). Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Annals of Oncology, 32(9), 1148–1156. https://doi.org/10.1016/j.annonc.2021.06.002